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POT1 and TPP1 are part of the shelterin complex and are essential for telomere length
regulation and maintenance. Naturally occurring mutations of the telomeric POT1–TPP1
complex are implicated in familial glioma, melanoma and chronic lymphocytic leukaemia.
Here we report the atomic structure of the interacting portion of the human telomeric POT1–
TPP1 complex and suggest how several of these mutations contribute to malignant cancer.
The POT1 C-terminus (POT1C) forms a bilobal structure consisting of an OB-fold and a
holiday junction resolvase domain. TPP1 consists of several loops and helices involved in
extensive interactions with POT1C. Biochemical data shows that several of the cancer-
associated mutations, partially disrupt the POT1–TPP1 complex, which affects its ability to
bind telomeric DNA efﬁciently. A defective POT1–TPP1 complex leads to longer and fragile
telomeres, which in turn promotes genomic instability and cancer.
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S
helterin is a hexameric nucleoprotein complex responsible
for maintaining the integrity of the ends of our chromo-
somes, known as telomeres1. Human shelterin consists of
TRF1, TRF2, TIN2, RAP1, POT1 and TPP1 (refs 1–3), binds
double and single-stranded telomeric DNA and is involved in a
wide range of functions4,5. It suppresses DNA damage response
by capping and protecting the ends of chromosomes from being
recognized as DNA double-strand breaks6,7. It prevents
exonuclease degradation by sequestering the telomeric
overhang8. It also controls telomere length by regulating access
of telomerase to the telomeric overhang9.
POT1 has a wide range of functions at telomeres all of which
are geared toward maintaining the integrity of the telomeric
overhang. POT1 binds single-stranded, telomeric DNA with high
afﬁnity and speciﬁcity4,10,11. POT1-DNA binding sequesters the
telomeric overhang, thus assisting in telomere capping,
downregulation of telomere elongation and ATR dependent
DNA damage response12–15. POT1 telomeric DNA binding is
mediated by the two N-terminal OB-folds of the protein, while
the C-terminal portion of the protein binds TPP1 (refs 10,16).
Human and S. pombe TPP1 binding to POT1 enhances its DNA
binding properties by 10-fold9,11,17,18. During the S-phase of the
cell cycle, the human POT1–TPP1 complex recruits telomerase to
telomeres9,16,19 via direct contacts of telomerase with the TEL
patch located at the N-terminal OB-fold of TPP1 (ref. 20).
Binding of POT1 to the telomeric overhang resolves
G-quadruplexes and allows for telomerase loading to telomeres
for telomere elongation21.
It was recently discovered that POT1 is frequently mutated in
chronic lymphocytic leukaemia, familial melanoma and
glioma22–27. There are currently 137 naturally occurring
mutations of POT1 reported to be associated with human
disease (cBioPortal for Cancer Genomics). Many of these
mutations localize at the N-terminal OB-folds and disrupt
POT1-DNA binding, while others are located at the C-terminus
of the protein and were TPP1 binds22–25. POT1 N-terminal
mutations primarily disrupt DNA-binding and are associated
with chromosomal abnormalities such as irregular telomere
length, fragile telomeres and chromosome end-to-end fusions,
phenotypes usually associated with telomere uncapping22–24,26,27.
However, the precise role of human POT1 C-terminal (POT1C)
mutations in human disease is currently unclear.
Here, we investigate the mechanism of POT1–TPP1 assembly
and how naturally occurring POT1 mutations contribute to
cancer. Our data shows that POT1C consists of two domains, an
OB-fold and a holiday junction resolvase (HJR) domain both of
which make extensive interactions with TPP1 forming a tight
heterodimer. Inspection of the structure reveals that several of
these mutations either perturb the POT1C fold and/or disrupt
POT1–TPP1 binding. Altering the natural state of the
POT1–TPP1 complex affects the integrity of the telomeric
overhang, leading to chromosomal abnormalities associated with
a dysfunctional telomere capping complex leading to genomic
instability and cancer.
Results
Structure of the human POT1–TPP1 complex. We generated
the interacting domains of human POT1 and TPP1 by limited
proteolysis and mass spec analysis of the full length POT1–TPP1
complex (Fig. 1a,b). POT1C consists of residues 330–634 and
TPP1 255–337 (TPP1(PBD)) (Fig. 1a,b). We solved the structure
by the single wavelength anomalous dispersion (SAD) method
and a Hg derivative (Table 1). The map showed clear electron
density for POT1C residues 332–633 and TPP1(PBD) residues
266–326 (Fig. 1c).
POT1C consists of a classic OB-fold and a holiday junction
resolvase domain (HJR) (Fig. 1d). The POT1C(OB) is a
canonical OB-fold and is structurally most similar to the
Oxytricha Nova Telomere End-Binding Protein (TEBPa, PDB
ID: 1OTC—RMSD¼ 2.2 Å—Fig. 1e). It is worth noting that an
overlay of the TEBP alpha and beta dimer (PDB ID: 1OTC
(ref. 28)) with that of the POT1–TPP1 structure shows no
similarities in the organization of the two heterodimers. The
organization of the six beta strands of the OB-fold forms a deep
and well deﬁned indentation on the surface of the protein, which
comprises the canonical binding pocket of an OB-fold (Fig. 1d).
Interestingly, the HJR is an insertion of the OB-fold and
comprises residues P392-L538. The HJR is structurally similar to
the Archaeoglobus fulgidus resolvase domain (AfHJR, PDB:ID
2WIW) with an RMSD 2.7 Å (Fig. 1f). HJR consists of seven
antiparallel beta-strands surrounded by ﬁve alpha helices (a3, 4,
5, 6, 7) (Fig. 1d,f). Structural comparison of POT1C (HJR) with
the AfHJR domain highlighted two distinct differences between
these two HJR domains. One difference lies with the organiza-
tion of the helices present in both HJR domains with four out of
the ﬁve helices not overlapping (Fig. 1f). Another striking
difference between the two HJR domains lies with the DNA
binding pocket of the HJR. In AfHJR double stranded DNA
binding is mediated primarily by two short antiparallel
b-strands located on the surface of the protein and away from
the ﬁve b-strands that form the core of the domain. In HJR,
these two strands have shifted by a 50 rotation and 18Å
translation and are an integral component of the beta-sheet
generated by all seven b-strands of this domain (Fig. 1f). The
HJR putative DNA binding pocket is occupied by helix a3, the
N-terminal helix of HJR. Extensive interactions between the two
POT1C domains generates a long, almost cylindrical structure
providing an extensive surface area for TPP1 binding. Further
stabilization of the bilobal POT1C structure is mediated by a
Zn2þ ion coordinated, tetra-cysteine cluster (C382, C385, C503,
C506) locate at the interface of the two domains (Fig. 1d).
TPP1(PBD) is an extended coil with four alpha helices
distributed throughout the protein. The TPP1 polypeptide spans
the entire length of POT1C and makes extensive contacts with
both of its domains (Fig. 1d). Interestingly, TPP1(PBD) is
organized in the opposite orientation (N—to—C-terminal) to
that of POT1C so that the N-terminal portion of TPP1(PBD) (a1)
interacts with the HJR while the C-terminal one interacts with the
OB-fold. In particular, a1 of TPP1(PBD) makes extensive
interactions with the surface of the b-sheet generated by the
b-strands of the HJR. It also interacts with helix a5 of POT1C,
which is located on the same face of the b-sheet of HJR and in
parallel orientation with the b-strands forming the b-sheet
(Fig. 1d). The TPP1(PBD) helix a1 is leucine/valine rich and the
majority of contacts with the POT1C, HJR are hydrophobic in
nature (Fig. 2a). TPP1, Leu271 is buried in the large hydrophobic
pocket formed by L445, F438 and F470 of POT1C. The side chain
of TPP1, L274 stacks against the side chain of POT1C, F470.
TPP1, V272 and A275 are coordinated by the side chains of
POT1C, F438 and W424. W424 of POT1C also makes a
productive hydrogen bond with E278. L279 is buried in a well-
deﬁned hydrophobic pocket formed on the surface of POT1C by
residues W424, V436, L466, V434 and the aliphatic portion of the
side chain of E462. L281 is also buried within this pocket of POT1
but the contacts are limited to the side chains of W424 and T426.
Contacts between the loop that connects the TPP1(PBD)
helices a1 and a2 and POT1C are limited to residues C285 and
P288. Both of these residues make minor hydrophobic interac-
tions with the OB-fold of POT1C. The loop is also held in place
by a 2.7 Å hydrogen bond between the backbone of this loop and
E394 of POT1C.
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The TPP1(PBD) helix a2 localizes at the interface of the
POT1C, OB-fold and HJR domains, where it is involved in
extensive and speciﬁc interactions with the protein (Fig. 2b). Of
note are the contacts generated by the highly conserved W293
and R297 of TPP1. The large W293 side chain is buried in a deep
hydrophobic pocket formed by the POT1 residues F542, V583,
V573, L574, F542, V378 and the aliphatic portion of Q580, which
comprise part of helices a2, a7 and a8 of the OB-fold. The side
chain of POT1, Q580 also hydrogen bonds the TPP1 a2 backbone
and the side chain of H292. R257 of TPP1 also localizes at the
interface of the OB and HJR of POT1C but unlike W293, its side
chain is involved in a network of interactions with POT1C via
solvent molecules (Fig. 2d). The only direct contact between R257
and POT1C involves a hydrogen bond with the backbone of
V391.
Additional contacts between TPP1 and the POT1C OB-fold are
extensive and involve helices a3 and a4 and the coils that connect
them (Fig. 2c). Both of these helices are docked into the
canonical, binding pocket of the OB-fold. More speciﬁcally, the
TPP1 Y306 side chain stacks against P371 of POT1C. The
branched side chains of TPP1, V308 and L313, are buried into a
greasy hydrophobic patch located at the base of the OB-fold’s
binding pocket. TPP1, I315 of the linker that connects a3 to a4
coordinates POT1 Y610, F625, and the aliphatic portion of the
K608 side chain. Contacts between the C-terminal helix (a4) of
TPP1 and POT1C are limited to L325 and the side chains of P357
and K608 of POT1C.
Several POT1C mutations reduce POT1–TPP1 binding. There
are several POT1C mutations (L343F, P446Q, P475L, R477T,
A532P, I535F, C591W and Q623H) that are associated with
either familial glioma, melanoma or CLL (refs 22–27)
(Supplementary Table 1). The majority of these mutations
(L343F, P446Q, P475L, R477T and C591W) are somatic and
speciﬁc to CLL (ref. 22), while A532P and Q623H are germline
and speciﬁc to familial glioma and melanoma24. To determine the
role of the POT1C disease mutations in POT1–TPP1 binding
and complex assembly, we performed Isothermal Titration
Calorimetry (ITC) measurements. The experiments were carried
out using puriﬁed, wild type (WT) TPP1(PBD) (residues 255–337)
and WT or mutant POT1C (residues 330–634) (Supplementary
Fig. 1), the same constructs we used for the crystallization of the
POT1C–TPP1(PBD) complex. The proteins were overexpressed
in Escherichia coli and puriﬁed to homogeneity using three
successive steps of puriﬁcation as described in the methods
section of the manuscript. All TPP1(PBD) and POT1C, WT and
mutant proteins, except for I535F, overexpressed stably and in
sufﬁcient quantities for the proposed studies (Supplementary
Fig. 1).
Considering the extensive network of interactions between the
two proteins it is not surprising that the binding constant of TPP1
for POT1 is in the nanomolar range (Kd¼ 120±16 nM—
Fig. 3b,f). Of the seven mutant POT1C proteins tested, only
P446Q, C591W, and Q623H showed signiﬁcant loss of TPP1
binding (Kds of 289, 870 and 471 nM, respectively—Fig. 3c,g,h,i;
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Figure 1 | Crystal structure of the human telomeric POT1–TPP1 complex. (a) Primary structure of POT1 and TPP1 showing domains and their functional
properties. POT1C disease mutations (L343F, P446Q, P475L, R477T, A532P, C591W and Q623H) discussed in this manuscript are also indicated. (b) SDS–
page gel of the puriﬁed POT1C and TPP1(PBD) proteins used in structural and biochemical studies. (c) Stereo image of a portion (TPP1 bound to the OB-fold
of POT1) of the simulated annealing omit map at 1 sigma contour level. (d) X-ray Crystal structure of the human POT1C—TPP1(PBD) complex; The OB-fold
and HJR of POT1C are shown in blue and red colours respectively; TPP1(PBD) is shown in green colour. The Zn2þ ion coordinated by 4 cysteins (C382,
C385, C503 and C506—stick) is shown as a cyan sphere. (e) Overlay of the POT1C and the Oxytricha nova telomere end binding protein alpha subunit
(OnTEBPa—beige colour, PDB ID: 1OTC (ref. 28)) OB folds. (f) Overlay of the POT1C HJR (red colour) with its closest structural homologue Archaeoglobus
fulgidus HJR (AfHJR—cyan colour; PDB ID: 2WIW).
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Supplementary Table 2). P475L displayed a marginal decrease in
TPP1 binding (164±32 nM) but was not statistically signiﬁcant
(P¼ 0.22). In contrast, L343F, R477T and A532P displayed
almost WT TPP1 binding afﬁnity (Kds 114, 123 and 117 nM,
respectively—Fig. 3b,e,f,i and Supplementary Table 2). Consistent
with the POT1C-TPP1(PBD) structure presented here, P446 and
Q623 make direct contacts with TPP1, while the C591W
mutation most likely displaces a8 of the POT1C(OB) (Fig. 2e),
which indirectly affects TPP1 binding. P475 lies in the interior of
the HJR and contributes to the fold of this domain. L343, A532
and R477 are located away from the TPP1 binding sites of POT1
and are either involved in the fold of the protein (L343, A532) or
are solvent exposed (R477) and their function is currently
unclear.
POT1–TPP1 disruption does not alter telomerase processivity.
Since the POT1–TPP1 complex is directly linked to telomerase
processivity9,16, we asked whether the POT1C mutations,
associated with human disease, affect telomerase processivity. It
is worth noting that the TEL patch of TPP1 implicated in
telomerase binding is located at the N-terminus of TPP1. To
address this question, we performed direct telomerase activity
assays using cell extracts overexpressing super telomerase and at
saturated levels of full length, WT or mutant POT1–TPP1.
HEK293T cells extracts overexpressing human super-telomerase
(the super-telomerase plasmids were a gift of the Lingner lab)
were prepared as described by Lingner et al.29 We also
overexpressed and co-puriﬁed the full length POT1 and an
N-terminal truncation of TPP1 consisting of residues 87–544
((TPP1(87)) (Fig. 1a). The two proteins were overexpressed
separately in E. coli and the cells co-cracked to allow stable
POT1–TPP1 complex formation prior to puriﬁcation. We found
that independent puriﬁcation of the two proteins resulted in
partial TPP1 degradation suggesting that TPP1 is not stable alone
(Fig. 4a). We were unable to purify sufﬁcient amounts of the full-
length I535F POT1 mutant for this assay. In addition, we
prepared HEK293T lysates overexpressing human super-
telomerase, full-length POT1 and TPP1 as described by
Nandakumar et al.20. We examined the stability and levels of
WT and mutant POT1 and TPP1 proteins overexpressed in
transfected HEK293T cells using western blot analysis. Western
blot analysis shows that all proteins (WT and mutant POT1 and
TPP1) express at levels similar to the WT protein (Fig. 4b).
Both approaches show robust telomerase activity with
increased telomerase processivity in the presence of the WT
POT1–TPP1 complex (Fig. 4c–f and Supplementary Fig. 2),
consistent with what has been previously reported9. The POT1
mutants L343F, P475L, R477T, A532P and I535F showed WT
telomerase processivity (Fig. 4c–f), in agreement with the ITC
data, which shows that these mutant proteins bind TPP1 with
WT binding afﬁnity (Fig. 3,a,b,d–f and i). Unexpectedly, the
P446Q, C591W and Q623H POT1 mutants, which bind TPP1
with 2–7 fold less afﬁnity (Fig. 3c,g,h and i), also show WT
telomerase processivity within the margin of error (Fig. 4c–f).
Partial POT1–TPP1 disruption reduces POT1-DNA binding.
POT1 binds the telomeric overhang with high afﬁnity and
selectivity, a process enhanced by TPP1 binding11,17. For this
reason, we asked if the POT1 disease mutants located in the
C-terminal portion of the protein and where TPP1 binds, affect
POT1-DNA binding. Fluorescence Polarization (FP) assays using
a ﬂuorescently labelled DNA probe consisting of three telomeric
repeats (TTAGGG)3 (18mer) were carried out in the presence of
(a) the POT1C and TPP1(PBD) protein complex used for crystal
and ITC studies (Figs 1b and 3a) (b) full-length POT1 WT and
three mutant (P446Q, C591W, and Q623H) proteins and (c) the
E. coli puriﬁed, full-length WT and mutant (L343F, P446Q,
P475L, R477T, A532P, C591W and Q623H) POT1 and the
N-terminally truncated TPP1(87) used in the telomerase direct
assays (Fig. 5a).
FP data show that POT1C alone and the POT1C-TPP1(PBD)
complex do not bind single-stranded telomeric DNA (Fig. 5a).
The full-length WT and mutant (P446Q, C591W and Q623H)
POT1 proteins alone all bind single-stranded telomeric DNA with
a Kd of B20 nM (Fig. 5b,d; Supplementary Table 3). For the
POT1–TPP1 complex our data shows that the WT complex binds
the telomeric overhang with approximately 5.8±0.5 nM
(Fig. 5c,d and Supplementary Table 3), consistent with what’s
been reported previously4,9. Interestingly, the P446Q, P475L,
C591W and Q623H mutants show a decrease in DNA binding
afﬁnity (Kd¼ 10.3±1.0 nM, 10.7±1.4 nM, 15.6±2.5 and
8.9±1.0 nM respectively—Fig. 5c,d and Supplementary Table 3)
in agreement with the ITC data, which shows that these POT1
mutant proteins partially disrupt the POT1–TPP1 complex
(Fig. 3 and Supplementary Table 2). In addition, the L343F,
R477T and A532P POT1 mutants, which have wild type TPP1
binding afﬁnity (Fig. 3 and Supplementary Table 2) also bind
telomeric DNA with wild type afﬁnity (Fig. 5c,d and
Supplementary Table 3).
POT1C mutant proteins localize to telomeres. To determine
the impact of the POT1C mutations on telomere targeting, we
Table 1 | Data collection, phasing and reﬁnement statistics.
Native
(Zn data)
Phasing Hg
derivative 1
Data collection
Wavelength (Å) 1.0332 1.0000
Space group P4122 P4122
Cell dimensions
a, b, c (Å) 99.5 99.5 122.1 99.0 99.0 124.2
Resolution (Å) 38.6 2.1
(2.15 2.1)*
40–3.00 (3.08–
3.00)
I/sI 22.8 (2.7) 12.3 (3.5)
Completeness (%) 99.8 (100) 99.9 (100)
Redundancy 31.3 (31.4) 7.6 (7.6)
Phasing analysis
Resolution (Å) 40 3.00
Number of sites 5
Pseudo-free CC: 68.2
Mean ﬁgure of merit
(FOM)
0.605
Reﬁnement
Resolution (Å) 20-2.1 (2.16 2.10)
No. reﬂections 34,593 (2,473)
Rwork/ Rfree 18/22 (20.8/25.5)
No. atoms
Protein 2,858
Water 531
B-factors
Protein 40.4
Water 54.6
R.m.s deviations
Bond lengths (Å) 0.008
Bond angles () 1.233
Ramachandran plot (%)
Most favoured 98.9
Allowed 1.1
*Highest resolution shell is shown in parenthesis.
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co-expressed YFP-tagged POT1 with mCherry-tagged TRF2 in
HEK293T cells and used confocal imaging to examine their
localization. HEK293T cells were transiently transfected with
Cherry-TRF2 and YFP-POT1 and ﬁxed 24 h later. Western blot
analysis of whole-cell lysates of transfected HEK293T cells
showed overexpression of the WT and mutant YFP-POT1 pro-
teins (Fig. 6a). All of the POT1mutants co-localized with Cherry-
TRF2, similar to wild type, which indicates that the mutations do
not prevent POT1 telomere targeting (Fig. 6b).
Partial POT1–TPP1 disruption leads to longer telomeres. To
determine if the POT1 cancer mutations maintain telomere
length homoeostasis, we carried out southern blot analysis of WT
and mutant POT1 transfected HEK293T cells. Stable HEK293T
cell lines expressing Flag-POT1 were prepared using lentiviral
infection. We reduced the levels of endogenous POT1 using a
shRNA (shPOT1) targeting its 30UTR region (Fig. 7a). We also
generated two mock-treated control cell lines by co-infecting
HEK293T cells with the vector (not carrying the POT1 gene) and
with or without the shPOT1.
We conﬁrmed similar levels of exogenous WT and mutant
POT1 protein expression in the presence of shPOT1 in all cell
lines using western blot analysis (Fig. 7b). We ﬁnd that the length
of telomeric DNA for the vector alone (without shPOT1) remains
almost the same even after 70 population doublings (PD). In
contrast, the vector alone and the WT POT1 cell lines treated
with shPOT1 have signiﬁcant longer telomeres after 50 and 120
PD. More speciﬁcally, the average telomere length for the vector
alone without shPOT1 is B4.5 Kb. The telomere length of cells
transfected with the vector or WT POT1 and shPOT1 after 120
PD is B12.5 and 8.5 Kb, respectively. The cell lines transfected
with the POT1 mutants that partially disrupt the POT1–TPP1
complex and shPOT1 also have longer telomeres after 50 and 120
population doublings compared to the vector alone without
shPOT1 (Fig. 7c–f). The POT1 mutants P446Q, C591W and
Q623H, which partially disrupt the POT1–TPP1 complex showed
the most signiﬁcant change in telomere length. Approximately
4.5, 10 and 12.5 Kb increase in telomere length is observed for
P446Q, C591W and Q623H respectively (Fig. 7c–f), while L343F,
P475L, R477T, A532P and I535F show 3–5Kb increase in
telomere length (Fig. 7c–f).
Partial POT1–TPP1 disruption leads to fragile telomeres. To
better understand the role of the POT1 cancer-associated muta-
tions in telomere maintenance, we examined the phenotype of
HEK293T cells infected with WT or mutant POT1 (same as those
used for Southern blot analysis, Fig. 7b) using ﬂuorescence in situ
hybridization (FISH). The endogenous POT1 in these cell lines
was reduced by infection with shPOT1 (Fig. 7a). We prepared
metaphase spreads of these cell lines by ﬁxing the chromosomes
to microscope slides with formaldehyde, and hybridizing telo-
meres with a 50 TelC-Tamra peptide nucleic acid (PNA) probe.
Chromosomal DNA was stained with DAPI prior to imaging.
We counted the frequency of chromosome fusions, fragile
telomeres, and telomere free ends 50 population doublings after
infection. HEK293T cells carrying the empty vector showed an
average of 2–3% of chromosomes with chromosome fusions,
fragile and missing telomeres, similar to that of the cell line
overexpressing WT POT1. Elevated levels of fusions were
observed for the L343F (7%) and I535F (5%) POT1 mutants,
respectively (Fig. 8a,b). Interestingly, all POT1 mutants showed a
signiﬁcant increase of fragile telomeres (L343F 9%; P446Q, R477T
and Q623H, 9%; P475L and C591W 10%) compared toB3% for
the empty vector and WT POT1 (Fig. 8a,c). We also observed
elevated levels of missing telomeres in cells overexpressing L343F,
R477T (7%) and I535F (12%) POT1 mutants (Fig. 8a,d).
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Figure 2 | POT1C—TPP1(PBD) interactions. (a) Contacts between the POT1C OB-fold (blue) and the a3 and a4 helices of TPP1(PBD) (green); the disease
mutation L343F is shown in stick. (b) Extensive interactions between the POT1C-HJR (red) and the leucine rich a1 of TPP1(PBD) (green) are shown. The
P446Q and P475L mutations are highlighted with a box. (c) Contacts of the TPP1 helix a2 at the interface of the OB-fold and HJR of POT1C are shown. (d)
The R477T, A532P and I532F disease mutations form part of the HJR of POT1C. The position of these amino acids with respect to the nearest TPP1
structural element (a1–green colour) are shown. (e) Extensive interactions between the POT1C OB-fold (blue) and helices a3 and a4 of TPP1(PBD) (green)
are shown. The disease mutations C591W and Q623H are highlighted with a box.
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Discussion
The cancer phenotypes associated with POT1C naturally
occurring mutations are diverse (familial melanoma, glioma
and CLL (refs 22–25,27), Supplementary Table 1), which points
to the complex nature and function of the telomeric complex
POT1–TPP1 at telomeres. N-terminal, POT1 disease mutations
disrupt POT1-DNA binding and release the telomeric overhang,
which results in persistent telomere replication by telomerase22–25.
There is no evidence currently that supports POT1C or POT1C-
TPP1(PBD), DNA binding (Fig. 5a). However, POT1C interacts
with TPP1, and POT1 mutations that disrupt the complex would
be expected to inﬂuence its functions, which include localization to
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Figure 3 | ITC binding data for the POT1C and TPP1(PBD) proteins. (a–h) ITC binding data of WT and mutant (L343F, P446Q, P475L, R477T, A532P,
C591W and Q623H) POT1C with TPP1(PBD). (i) Bar graph of binding constants (Kd, mM) for WT and mutant POT1C proteins derived from the ﬁtted
ITC data. Three independent ITC experiments and a two-tailed Student’s t-test was performed with respect to WT: *Po0.05, **Po0.01. The data clearly
shows that the POT1C, P446Q, C591W and Q623H mutations reduce TPP1 binding.
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telomeres, stimulating telomerase processivity, and enhanced
POT1 DNA binding activity4,5,9. Moreover, the fact that a POT1
mutation confers a telomere instability phenotype, over a long
period of time might provide the genetic variation that is required
for clonal evolution. This would be even more apparent in tumours
with a high-tumour burden, such as CLL, where the total number
of cells will be in the 10–100 s of billions range. Thus, a
combination of the long time it takes for these tumours to
evolve and the tumour burden means that even subtle defects in
telomere stability could have a dramatic effect on long-term clinical
outcome.
Our data on several of the referenced disease associated POT1
mutations supports the above hypothesis. Cell imaging shows that
all reported POT1 mutant proteins localize to telomeres (Fig. 6).
Despite the fact that all POT1 mutant proteins localize to the
telomeric overhang, FP assays show that only the mutants
(P446Q, C591W and Q623H) that partially disrupt the POT1–
TPP1 complex display signiﬁcantly lower afﬁnity for telomeric
DNA (Figs 3 and 5c,d). Reduced afﬁnity of the POT1–TPP1
complex for the telomeric overhang will result in persistent
telomere elongation by telomerase30. Persistent telomerase action
at the end of chromosomes will generate longer telomeres than
those observed for the WT POT1–TPP1 complex (Fig. 7c,d). This
observation is consistent with the Southern blot analysis
presented here, which shows that HEK293T cells transfected
with the POT1C mutants have longer telomeres than the cells
transfected with WT POT1. This observation is particularly
distinct for the POT1 mutants that partially disrupt the POT1–
TPP1 complex with B4.5, 10 and 12.5 Kb increase in telomere
length for P446Q, C591W and Q623H respectively (Fig. 7). It has
also been well established that unregulated telomere length results
in chromosomal abnormalities associated with telomere signal
free ends and fragile telomeres31–33. Consistent with this
hypothesis POT1 mutations that disrupt the POT1–TPP1
complex show elevated levels of missing and fragile telomeres
(Fig. 8). This defect is particularly prominent when it comes to
fragile telomeres with an average of 10% of fragile telomeres for
all POT1 mutants when compared to B3% for the empty vector
and WT POT1. Interestingly, none of the disease mutations
appear to affect telomerase processivity (Fig. 4c–f).
kDa
TERT
αPOT1
αTERT
TERT
POT1
TPP1
αTPP1
αActin
POT1 –
–
–
– –
–
–
–
– – –
– –
+
+
+ +
+
+
+
+
+ +
+ +
+
+ +
+
+ +
+
+
+
+ +
+
+ +
+
+ +
+
+ +
+
+
+
+ ++ + +
+++ ++
+
++ – – –+ + +++ ++++
+ + – – – + + ++ + + +
+
++ +
TPP1(87)
POT1
TPP1
POT1
TPP1
+25
+20
+15
+25
+20
+15
+9
+10 +10
+8
+7
+6
+5
+4
+3
+2
+9
+8
+7
+6
+5
+4
+3
+2
+1
Loading
control
(LC)
+1
M PO
T1
2 
μg
 S
TE
2 
μg
 S
TE
5 
μg
 S
TE
PO
T1
ST
E
Co
nt
ro
l
PO
T1
2 μ
g S
TE
5 μ
g S
TE
TP
P1 WT
L3
43
F
P4
46
Q
P4
75
L
R4
77
T
A5
32
P
C5
91
W
Q6
23H
PO
T1
TP
P1 WT
L3
43
F
P4
46
Q
P4
75
L
R4
77
T
A5
32
P
I53
5F
C5
91
W
Q6
23H
PO
T1TP
P1
TP
P1
TP
P1W
T
W
T
W
TL3
43
F
L3
43
F
L3
43
F
P4
46
Q
P4
46
Q
P4
46
Q
P4
75
L
P4
75
L
P4
75
L
R
47
7T
R
47
7T
R
47
7T
A5
32
P
A5
32
P
A5
32
P
C5
91
W
C5
91
W
I5
35
F
C5
91
W
Q6
23
H
Q6
23
H
Q6
23
H
LC PO
T1
TP
P1
W
T
L3
43
F
P4
46
Q
P4
75
L
R
47
7T
A5
32
P
C5
91
W
I5
35
F
Q6
23
H
LC250
130
100
1.2
R
el
at
ive
 p
ro
ce
ss
ivi
ty
 to
W
T 
PO
T1
-T
PP
1
R
el
at
ive
 p
ro
ce
ss
ivi
ty
 to
W
T 
PO
T1
-T
PP
1
1.0
0.8
0.6
0.4
0.2
0.0
1.2
1.0
0.8
0.6
0.4
0.2
0.0
70
55
b
a
e
f
c d
Figure 4 | Telomerase direct activity assays. (a) SDS–PAGE gel of super-telomerase extract (STE) and E. coli puriﬁed full-length POT1 (ﬂPOT1) and
TPP1(87) proteins used in the direct assay of (c). The red arrow indicates where TERT is expected to run (B130 kDa). The assay in c was carried out in the
presence of 150 nM of puriﬁed POT1–TPP1 complex. (b) Western blot of HEK293T lysates used in the direct assay of panel (d). The gel shows the levels of
transiently expressed POT1 and TPP1 are much higher than those of TERT, conﬁrming that the direct assays were carried out at saturating levels of POT1
and TPP1. (c) Telomerase direct activity assay using 2 mg of STE; 150 nM puriﬁed WTor mutant (L343F, P466Q, P475L, R477T, A532P, I535F, C591W and
Q623H) ﬂPOT1; 150 nM WT TPP1(87); and 20 nM of primer A5 (TTAGGGTTAGCGTTAGGG). (d) Telomerase direct activity assay using 5 mg of STE co-
transfected with WT or mutant (L343F, P466Q, P475L, R477T, A532P, C591W and Q623H) ﬂPOT1 and WT full-length TPP1 (ﬂTPP1). The STE was
supplemented with 20 nM of A5 primer. The number of telomeric repeats added to the primer are indicated on the right of the gels (c and d,e and f)
Quantiﬁcation of telomerase processivity of panels (c) and (d) respectively. The values are the average of four independent experiments; error bars
indicate s.d.
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We show that several of the referenced POT1 mutations
(P446Q, C591W and Q623H) partially disrupt the POT1–TPP1
complex (Fig. 3c,d,g–i). This observation is in agreement with the
POT1–TPP1 structure (Fig. 2), as well as data previously reported
by Liu et al.3, which shows that the 417–445 and 616–628 of
POT1 peptides make direct contacts with TPP1. P446Q is critical
for TPP1 binding as it comprises part of the loop that connects
the HJR strands b6 and b7 and coordinates L271 of the
N-terminal helix a1 of TPP1 (Fig. 2b). The P475L mutant
exhibits marginal disruption of the POT1–TPP1 complex forms
part of b8 located at the core of HJR domain and contributes to
the fold of this domain (Fig. 2b). The proline to leucine change
most likely subtly perturbs the organization of the structural
elements of the HJR domain surrounding this residue including
the re-organization of helix a5, which makes extensive
interactions with a1 of TPP1, thus affecting POT1–TPP1
binding (Fig. 2b). C591W is located at the C-terminus of helix
a8, which spans the entire length of the side of the OB-fold and
plays a critical role in the organization of this domain of POT1C
(Fig. 2e). Moreover, the N-terminal portion of helix a8 makes
extensive interactions with helix a2 of TPP1 and in particular the
side chain of W293. Displacement of the POT1 helix a8 would
lead to re-organization of this region of POT1C(OB), thus
affecting TPP1 binding. The POT1–TPP1 structure also shows
that Q623 directly engages TPP1 (Fig. 2e). The Q623 residue is
located at the heart of the canonical binding pocket of the POT1C
OB-fold, and the solvent accessible side chain coordinates the
backbone of helix a3 of TPP1. More speciﬁcally, the NE2 of Q623
makes a productive hydrogen bond with the carboxyl of L313 of
TPP1. Introduction of the larger hydrophobic side chain in this
position would lead to loss of this hydrogen bond and
rearrangement of the helix from its current position. Structural
reorganization of helix a3 would affect the extensive network of
interactions mediated between the residues V308, L313 and I315
of helix a3 and its connecting loops of TPP1 with V543, Y558,
M560, Y610 and F625 of the POT1C OB-fold, thus affecting
POT1–TPP1 binding.
Unlike P446Q, C591W and Q623H, the L343F, P475L, R477T
and A532P POT1C mutants displayed WT, TPP1 and DNA
binding afﬁnity (Figs 3 and 5). L343F comprises part of the loop
that connects the POT1C, OB-fold, b-strand b1 to the a-helix a1.
L343 is important for the structural organization of this loop and
does not make direct contacts with TPP1 (Fig. 2a). Similarly,
R477T is part of the b8 of HJR and is located at the opposite face
of this domain and where helix a1 of TPP1 binds (Fig. 2d).
Unlike L343, R477 is solvent exposed and does not make any
contacts with TPP1; in fact, the nearest TPP1 contact point is
B18Å away. A532 is part of a7 of POT1(HJR) and like R477, is
located on the opposite side of the HJR domain where helix a1 of
TPP1 binds. I535 is located in a7 of the HJR domain with the
hydrophobic side chain buried into the core of this domain.
Introducing the larger phenylaline side chain would disrupt the
core of the HJR domain and therefore lead to the destabilization
of the protein (Fig. 2d). Interestingly, isolation of the A532P and
in particular of I535F POT1C and ﬂPOT1 mutant proteins
resulted in lower levels of proteins compared to WT protein
(Supplementary Fig. 1b,c). This ﬁnding suggests that the A to P
and I to F amino acid changes of A532 and I535 residues most
likely affects the stability of these mutant POT1 proteins.
Isolation of the I535F protein did not produce adequate amounts
of this polypeptide for TPP1 and DNA binding assays. However,
these mutant proteins appear to be at WT levels in cell based
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Figure 5 | POT1–TPP1 telomeric DNA binding assays. (a) FP assays of POT1C and the POT1C–TPP1(PBD) complex with a single-stranded DNA probe
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and a two-tailed Student’s t-test was performed with respect to WT POT1–TPP1(PBD) complex: *Po0.05, **Po0.01.
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assays allowing us to study their effect in telomerase activity,
processivity, telomere localization and telomere defects including
telomere length, and chromosomal abnormalities (Figs 4, 6–8).
Southern blot analysis showed telomere length changes of
B3–5Kb—Fig. 7d,e. There is also a signiﬁcant increase in
telomere fusions, fragile and missing telomeres in the telomeric
FISH staining for the I535F mutant (Fig. 8).
Taken together our data show that it is a conﬂuence of factors
that contribute to malignant effects associated with POT1C
mutants. Some of these mutations (P446Q, C591W and Q623H)
partially disrupt the POT1–TPP1 complex and the DNA binding
afﬁnity of POT1, which in turn affects the ability of the complex
to regulate telomerase access to telomeres efﬁciently. Deregula-
tion of telomerase activity at the chromosomal terminus would
result in constitutive telomeric elongation and increased pro-
liferative potential23. In part, POT1 regulates telomere length34–37,
by regulating access of telomerase to telomeres, an effect
modulated by TPP1 binding9,21,38,39. Partial disruption of the
POT1–TPP1 complex could therefore lead to persistent access of
telomerase to the telomeric overhang and result in longer, fragile
telomeres.
Surprisingly, a set of the reported disease mutations (L343F,
A532P and R477T) do not appear to have a signiﬁcant effect in
the assembly of the POT1–TPP1 complex as indicated by our
structural and biochemical data (Figs 2–7). It is however worth
noting that all of these mutations show a signiﬁcant increase in
fragile telomeres with defects in telomere length, missing
telomeres and chromosome fusions. The precise role of these
mutations in POT1–TPP1 function are currently unclear and
further studies are required to better understand their role in
cancer.
Germline variants in POT1 have been detected in familial
melanoma and glioma22–25. Somatic mutations have been
identiﬁed in POT1 and has been identiﬁed as a susceptibility
locus for CLL (ref. 40). Somatic mutations in POT1 have also
been identiﬁed in CLL B-cell clones and whilst the impact of these
mutations on telomere length has not been established they are
associated with increased chromosomal instability22. It is worth
noting that POT1 mutations drive carcinogenesis in melanoma,
glioma and CLL patients usually in combination with an array of
other defective genes, such as CDKN2A, CDK4, BAP1, Notch1,
SF3B1, TP53 and ATM, which have already been identiﬁed to
predispose patients to these malignant diseases. Stratiﬁcation of
CLL patients based on the telomere length of their CLL B-cell
clones, reveals that those with short telomeres, within the length
ranges in which telomere fusion can be detected, exhibit an
extremely poor prognosis41. This is presumed to arise as a
consequence of telomere driven genome instability, clonal
evolution and tumour progression27. While the majority of
patients with long telomeres exhibit a better prognosis and a
more stable genome, a subset of patients still progress with their
disease. It will thus be of interest to examine the relationship
between somatic POT1 mutation, telomere length and
chromosomal instability and how this impacts on disease
progression.
Methods
Protein expression and puriﬁcation. Human POT1C, comprising residues
330–634, was identiﬁed via limited proteolysis and cloned into a pET28b vector
containing a N-terminal hexahistidine—pMocr fusion tag, cleavable by TEV pro-
tease. The TPP1(PBD) construct was designed to contain residues 255–337 and
was cloned into a pET28b vector containing a N-terminal hexahistidine tag clea-
vable by TEV protease. Both POT1C and TPP1(PBD) were overexpressed in E. coli
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Figure 6 | Cell imaging for localization of WTand mutant POT1 to telomeres. (a) Western blot showing the levels of YFP tagged, WTand mutant (L343F,
P466Q, P475L, R477T, A532P, I535F, C591Wand Q623H) full length POT1. We used GFP (aGFP) or POT1 (aPOT1) to detect the levels of YFP-POT1 in each
cell line. The band at 71 kDa and below the YFP-aPOT1 is a non speciﬁc protein. GAPDH was used as a loading control. (b) Maximum projection images of
co-localization of YFP-POT1 (green) and Cherry-TRF2 (red) proteins are shown. Merged images include DAPI. Scale bar, 5 mm. The data clearly shows co-
localization of WT and mutant ﬂPOT1 proteins to telomeres.
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ScarabXpress T7 lac competent cells (Scarab Genomics) at 18 and 30 C for 4 h,
respectively, using 1mM IPTG (isopropyl-b-D-thiogalactopyranoside; Gold
Biotechnology). The cells were harvested by centrifugation and lysed in a buffer
containing 25mM Tris–HCl, pH 7.5, 1.0M KCl, 1.0M Urea, 5% glycerol, 1mM
phenylmethylsulfonyl ﬂuoride (PMSF), and 1mM benzamidine (Ni Buffer A) via
sonication. The proteins were puriﬁed over a Ni-nitrilotriacetic acid (Ni-NTA -
MCLab) column, buffer exchanged while on the Ni-NTA column with 25mM
Tris–HCl, pH 7.5, 0.2M KCl and 5% glycerol (Ni Buffer C). The complex was
eluted with 300mM imidazole onto a tandem HS(poros)—HQ(poros) columns
(Applied Biosystems) equilibrated with Ni Buffer C. The HS–HQ columns were
then detached and the POT1C-TPP1(PBD) complex was eluted from the HQ
column with a salt gradient of 0.2M KCl to 1.0M KCl. The fusion tags were
cleaved by TEV overnight at 4 C and removed from the sample by an additional
step of Poros-HS and HQ. The clean complex was passed over a Superdex S200
(GE Healthcare) to remove any aggregates.
Full-length WT and mutant POT1 were cloned into the same vector as POT1C.
TPP1(87–544) was cloned into a pET28b vector containing an N-terminal
hexahistidine-MBP (maltose binding protein) cleavable by TEV protease. POT1
and TPP1 were overexpressed separately in ScarabXpress cells at 18 C overnight
using 1mM IPTG. The cells were harvested by centrifugation and lysed in Ni
buffer A via sonication. The proteins were ﬁrst puriﬁed over a Ni-NTA column and
then eluted onto an amylose column (New England Biotech) to further purify the
POT1–TPP1 complex and remove excess POT1 before eluting with a buffer
containing 25mM Tris–HCl, pH 7.5, 0.5M KCl, 5% glycerol, 1mM DTT and
30mM maltose. The fusion tags were cleaved with TEV protease overnight at 4 C.
The POT1–TPP1 complex was then buffer exchanged to remove the maltose and
passed over an orthogonal Ni-NTA and amylose column to remove any residue
fusion tags and TEV protease from the samples. The puriﬁed full-length POT1–
TPP1 complex was then concentrated and ran on an SDS–PAGE gel with known
concentrations of BSA standard and quantiﬁed using ImageQuant TL (GE
Healthcare) to determine the concentration of the complex.
Protein crystallization and structure determination. POT1C-TPP1(PBD),
crystal screening produced a crystal hit under sitting-drop vapour diffusion at
room temperature in a crystallization buffer containing 2.4M KCl, 50mMK/Na
Tartrate, 20mM BaCl2, and 0.1M Sodium Citrate, pH 5.5. (A longer construct of
POT1C consisting of residues 325–634 produced a different crystal form that
belonged to the P1 space group and diffracted to 3Å at best.) The new crystal form
belongs to the P4122 (sg91, 1 copy in asymmetric unit) and diffracted to 2.1 Å. The
native data set (containing Zn) was collected from 2 crystals at 1.03317Å wave-
length at BL12-2 SSRL to 2.1 Å resolution. The radiation damage was slowed with a
careful absorbed dose estimate, allowing high-multiplicity and accumulating a
signiﬁcant anomalous signal from the present Zn and Sulfurs in the protein. Both
the native and derivative data were processed with XDS (autoxds script at SSRL)
with a zero dose correction.
The structure was solved using a single methyl mercury (meHg) derivative
using the SAD approach as implemented in SHELXCDE using the graphical
interface of the HKL2MAP software. SHELXD identiﬁed ﬁve well deﬁned Hg sites
and SHELXE extended and optimized the initial phases to 2.1 Å and generated a
preliminary structure of 330 residues with excellent contrast (0.943) and
connectivity (0.843) resulting in FOM of 0.605. Subsequently the model was traced
using 10 cycles of BUCCANEER. The resulting model was almost complete—358
sequenced residues. The remaining model was improved in COOT and reﬁned
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Figure 7 | Southern blot analysis of WT and mutant POT1. (a) Quantitative RT-PCR showing knock down of endogenous POT1 mRNA, normalized to
GAPDH transcript levels, after lentiviral infection of HEK293T cells with shPOT1 and WT Flag-POT1; selection was carried out with puromycin and
blasticidin;±s.d. (n¼ 3). (b) Western blot showing WT and mutant POT1 protein expression levels in HEK293T cells expressing shPOT1 and Flag-POT1.
Cells infected with the empty pLU and pLKO.1 lentiviral vectors are used as controls. (c,d,e) Southern blot of HEK293T cells expressing shPOT1 and WTor
mutant ﬂPOT1. DNA from 5, 50 and 120 populations doublings (PD) is shown. DNA length standards are indicated along the left and right of the gels. The
white dashed line indicates the average telomere length of HEK293T cells transfected with the vector alone and no shPOT1 after 5, 50 and 120 PD. The
vector (- shPOT1), vector (þ shPOT1) and WT POT1 (þ shPOT1) controls are indicated with a green and yellow dot respectively. The POT1 mutants
(L343F, P466Q, P475L, R477T, A532P, I535F, C591W and Q623H) are indicated with red dots. (f) Quantiﬁcation of the mean telomere length (kb) from
panels (c,d and e). The same colour scheme as in panels c,d and e is used. Black bars indicate the range of telomere restriction fragments (TRF).
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with BUSTER (version 2.10.2). The reﬁnement converged to R/Rfree¼ 17.3/19.3%
to 2.1 Å resolution. The model has excellent stereochemistry as examined by
MOLPROBITY server (http://molprobity.biochem.duke.edu/).
Isothermal titration calorimetry (ITC). We carried out ITC experiments on a
MicroCal iTC200 (Malvern) using separately puriﬁed TPP1(PDB) and WT and
mutant POT1C proteins. The puriﬁed proteins were buffer exchanged into a buffer
containing 25mM Hepes, pH 7.5, 0.1M KCl, 5% glycerol, and 1mM TCEP.
Protein concentration was measured using a Bradford Assay42. TPP1(PBD) at a
concentration of 100 mM was injected into a cell containing 10 mM POT1C until
saturation was reached. For the ITC experiment, the cell of the calorimeter was
kept at 25 C, and the volume of each injection was 2.47 ml with a total of 16
injections. Analysis of the ITC data used the Origin analysis software
(GE Healthcare) to obtain binding constants and ratios.
Fluorescence polarization (FP) assays. We performed FP DNA binding assays
using an Envision Xcite Multilabel Plate Reader (Perkin Elmer). 20 ml binding
reactions were carried out in a buffer containing 20mM Hepes, pH 7.5, 100mM
KCl, 2mM MgCl2, 1mM EDTA, 2mM DTT, 1mgml 1 BSA, 5% v/v glycerol and
75 nM polyT50 competitor (IDT). The 18mer DNA probe (TTAGGGT-
TAGGGTTAGGG) was purchased with a 50 6-FAM label from IDT. The ﬁnal
probe concentration used was 2.5 nM, while the POT1–TPP1 protein concentra-
tion ranged from 0 to 100 nM or POT1C-TPP1(PBD) concentrations ranged from
0 to 5 mM. The reactions were incubated at room temperature for 30min and
pipetted in triplicate into a black 384 well optiplate (PerkinElmer). The reactions
were excited with 480 nm light and the emissions were measured at 535 nm light.
The milipolarization (mP) values were calculated by the Envision operating soft-
ware (PerkinElmer). The data was ﬁt and the binding constants were determined
with a one-site binding, nonlinear regression model using PRISM 5.0 (GraphPad
Software, San Diego California USA, www.graphpad.com).
Cell culture. The WT and mutant full-length human POT1 genes were cloned in
the pLU-EF1A-iBlast (pLU) vector with an N-terminal 1xFlag tag and 4 mg of
vector was used to transfect HEK 293T cells using lipofectomine 2000 (Invitrogen)
to test expression. HEK293T cells were cultured in growth medium containing
Dulbecco’s modiﬁed Eagle medium (Cellgro) supplemented with 10% fetal bovine
serum (Sigma) and 100 units ml 1 penicillin and 100mgml 1 streptomycin
(Sigma). All human cells were cultured at 37 C with 5% CO2 and harvested 48 h
after transfection.
Stable HEK293T cell lines overexpressing 1xFlag-POT1 were carried out using
lentiviral infection to deliver WT and mutant human POT1 genes in the pLU
vector with blasticidin resistance. A pLKO.1 vector with puromycin resistance
carrying the shRNA (TRCN0000009837) targeting the 30UTR of endogenous POT1
(shPOT1) was obtained from the Sigma Mission shRNA library and was delivered
with lentiviral infection. Lentiviral particles were prepared by lipofectomine 2000
(Invitrogen) transfection of HEK293T cells with the pLU or pLKO.1 and lentiviral
production vectors. Growth media was spiked with 5 mgml 1 blasticidin S, and
2 mgml 1 puromycin.
Western blot. For the western blot analysis of HEK293T cells co-transfected with
hTERT, hTER, POT1 and TPP1, standard immunoblot protocols were used with
the following antibody dilutions: anti-human TERT (abx120550, Abbexa, 1:1,000,
dilution), anti-human POT1 antibody (ab21283, Abcam, 1:1,000 dilution), anti-
human ACD (SAB2100024, Sigma, 1:1,000 dilution), anti-Actin antibody con-
jugated to HRP (A3854, Sigma, 1:1,000 dilution), and secondary HRP-conjugated
anti-sheep IgG (sc-2924, Santa Cruz, 1:1,000) and anti-rabbit IgG (A0545, Sigma,
1:1,000 dilution) were used to detect the human TERT and human POT1 and
TPP1 antibody, respectively.
For western blot analysis of HEK293T cells stably expressing shPOT1 and WT
and mutant POT1 proteins, standard immunoblot protocols were used with the
following antibody dilutions: anti-human POT1 antibody (P0096, Sigma, 1:1,000
dilution), anti-GAPDH antibody conjugated to HRP (2118S; Cell Signaling
Technology, Danvers, MA; 1:5,000 dilution), and secondary HRP-conjugated anti-
rabbit IgG antibody (A0545, Sigma, 1:1,000 dilution) was used to detect the human
POT1 antibody.
For the western blot analysis of YFP tagged WT and mutant POT1, standard
immunoblot protocols were used with the following antibody dilutions: anti-GFP
antibody (11814460001 Sigma, 1:2,000 dilution), anti-human POT1 antibody
(ab21382 Abcam, 1:1,000 dilution), anti-GAPDH antibody conjugated to HRP
(2118S Cell Signaling Technology; 1:5,000 dilution), and secondary HRP-
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Figure 8 | Fluorescence in situ hybridization data. (a) Telomeric FISH metaphase spreads of cells expressing WT and mutant (L343F, P466Q, P475L,
R477T, A532P, I535F, C591W and Q623H) ﬂPOT1 proteins after 50 population doublings (Red, TelC-Tamra; blue, DAPI). Endogenous POT1 levels were
reduced with shPOT1. Telomere fusions, fragile telomeres and missing telomeres are indicated by red, pink and green arrows respectively. Scale bar is 5 mm.
(b-d), Quantiﬁcation of telomere fusions, fragile, and missing telomeres from the metaphase spreads of (a). Bars indicate the per cent of metaphase events.
Error bars are indicating s.d. An average of 500 chromosomes were counted in each experiment.
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conjugated anti-rabbit IgG antibody (A0545, Sigma, 1:1,000 dilution) was used to
detect the human POT1 antibody.
Detection of antibody signal was done with chemiluminescence activated using
2ml of Luminata Forte Western HRP Substrate (Millipore). The signal was
detected and developed with a Fuji LAS-3000 scanner. Western blot signals were
quantiﬁed using ImageQuant TL (GE Healthcare) and normalized using the
b-Actin or GAPDH signal as a loading control.
Reverse transcription PCR and quantitative PCR analyses. To test the effec-
tiveness of the shRNA targeting the 30UTR of endogenous POT1, we collected
RNA from cells treated with shRNA by lysing pelleted cells in TRizol (Life
Technologies) and puriﬁed RNA using the Direct-zol RNA mini prep kit (Zymo
Research, Irvine CA). Reverse transcription PCR was performed using random
hexamer primers followed by quantitative PCR using primers in 30-UTR of POT1.
The following primer pairs were used to measure human POT1 and GAPDH
mRNA levels after knockdown: POT1 (50CTCACCTTCCCTGTTTGAGCTT30 and
50TCCCATACCCATGCTAACATCA30); GAPDH (50ATGGAAATCCCATCACC
ATCTT30 and 50CGCCCCACTTGATTTTGG30).
Direct telomerase activity assays. Telomerase preparations were carried out as
previous described by Cristofari et al43. Brieﬂy, super telomerase extracts were
prepared by lysing HEK293T cells overexpressing human TERT and TER
(pcDNA6-hTERT and pBS-U1-hTER plasmids were a gift from J. Lingner) in
CHAPS lysis buffer consisting of 150mM KCl, 50mM Hepes, pH 7.5, 1mM
MgCl2, 1mM EDTA, 10% glycerol, 0.5% CHAPS, 5mM beta-mercaptoethanol and
0.01 ml ml 1 of protease inhibitor cocktail (Sigma P8340). Direct assays were
carried out with 150 nM of puriﬁed full-length POT1 or TPP1 incubated with
20 nM of A5 primer (TTAGGGTTAGCGTTAGGG) before the addition of 2 mg of
super telomerase extract. In addition, direct assays were also performed with 5 mg
of lysates from HEK293Tþ shPOT1 cells transiently transfected with 1 mg of
pcDNA6-hTERT and 3mg of pBS-U1-hTER plasmids. For transfections involving
POT1 or TPP1, 1mg of pLU-1xFlag-POT1 or pLU-1xHA-hTPP1 plasmid was used.
In control transfections where POT1 or TPP1 were omitted, 1 mg of pLU-EF1A-
iBlast (empty vector) was included.
Telomerase extension reactions were carried out in 20 ml at 30 C for 60min,
50mM Tris–HCl, pH 8.0, 50mM KCl, 1mM spermidine, 1mM MgCl2, 5mm
b-mercaptoethanol, 500mM dATP, 500 mM dTTP, mM dGTP, 20mCi of [a-32P]—
dGTP (3,000 Cimmol 1). Reactions were stopped with the addition of 100ml of
3.6M ammonia acetate, 20 mg of glycogen, 0.5 nM of 50 32P-labelled 18mer loading
control, and were precipitated overnight with 500 ml of ethanol at  80 C. The
samples were pelleted by centrifugation at 14,000 RPM at 4 C for 20min, washed
with 500ml of 70% ethanol, centrifuged again for 10min. The ethanol was removed
from each sample and then air dried for 30min. The pellets were then resuspended
in a loading buffer containing 98% formamide, 1mM EDTA, and 0.05% xylene
cyanol, heated to 95 C for 5min, and then loaded onto a 10% acrylamide, 7M
urea, 1 TBE sequencing gel. The gel was run for 3.5 h at 1,800V, ﬁxed with 30%
Methanol 10% acetic acid solution and dried for 1 h with a gel dryer (Bio-Rad). The
dried gel was then exposed to a phosphorous storage plate overnight and imaged
the next day with a Typhoon 9410 Imager (GE Healthcare). Quantiﬁcation of
telomerase products was measured using ImageQuant TL software (GE
Healthcare). Calculation of telomerase processivity was performed as described
previously9,44. Brieﬂy, each band was quantiﬁed using ImagequantTL (GE
Healthcare) and the intensity was normalized against the loading control. Band
intensity was then corrected for the number of radiolabeled nucleotides (hot Gs)
added per repeat. The total lane counts (TLCs) were then measured by taking the
sum of the normalized band intensity over the entire lane. Each corrected band was
expressed as a fraction left behind (%LB) by summing the normalized intensity for
each repeat and every repeat below it, divided by the total counts of every repeat in
the lane (TLCs) and multiplied by 100. The natural log of (100-%LB) was then
calculated and plotted for every repeat number. The plot of ln(100-%LB) per repeat
number was ﬁt with a linear regression equation with a slope m. The processivity
was then calculated by taking –ln(2)/m for the slope of each line (Supplementary
Fig. 2).
Cell imaging. Human full-length TRF2 and WT and mutant POT1 genes were
cloned into modiﬁed pEGFP-C3 vectors (BD Biosciences Clontech) carrying the
YFP or mCherry N-terminal fusion tags. HEK 293 cells were transiently transfected
with Cherry-TRF2 and YFP-POT1 plasmids using Fugene 6 (Promega, Madison
WI) transfection for 24 h. Cells were ﬁxed with freshly prepared paraformaldehyde
(4% at room temperature) and stained with DAPI.
Confocal images were taken with a Leica SP8X white light laser scanning
confocal microscope (Leica Microsystems, Buffalo Grove, IL) using a  63 oil
objective lens (numerical aperture 1.4) with  6 zoom. For each cell, stacks ofB15
images with 0.5 mm step sizes were acquired and processed using Huygens
deconvolution software (Scientiﬁc Volume Imaging, The Netherlands). The ﬁles
were then presented as maximum projection images using Leica LASX software.
Southern blot. For telomere length analysis we carried out Southern blots on
HEK293T cells stably expressing WT and mutant 1xFlag-POT1 and an shRNA
targeting the 30UTR of the endogenous POT1. Genomic DNA from cells at various
passages was puriﬁed using a QIAamp DNA mini kit (Qiagen) and 10 mg of
genomic DNA was then digested with AluIþMboI restriction endonucleases. 50
32P-labelled GeneRuler 1 kb Plus DNA ladder (Thermo) and 2 mg of digested DNA
was then fractionated in a 0.7% agarose gel, denatured and transferred onto a
GeneScreen Plys hybridization membrane (Perkin Elmer) overnight. The mem-
brane was cross-linked, hybridized at 42 C with 50-end-labaled 32P-(TTAGGG)4
probe in Church buffer (0.5 N Na2HPO4, pH 7.2, 7% SDS, 1% BSA, 1mM EDTA)
overnight and then washed three times for 20min each with wash buffer (0.2M
Na2HPO4, pH 7.2, 1mM EDA, and 2% SDS) at 37 C. The membrane was exposed
to a phosphorous storage plate overnight and visualized by Typhoon 9410 Imager
(GE Healthcare). Telomere length was calculated using the software TeloTool
(MATLAB)45.
Fluorescence in situ hybridization. HEK293T cells stably expressing WT and
mutant 1xFlag-POT1 and an shRNA targeting the 3’UTR of the endogenous POT1
were passaged 10 times (B50 population doublings) and grown to 40% conﬂuence
on a 10 cm plate and treated with 100mgml 1 of colcemid for 4 h. Cells were then
trypsinized to detach them from the plate, pelleted and treated in a hypertonic
environment (75mM KCl for 30min at 37 C). Cells were then ﬁxed in 10ml of 3:1
methanol:acetic acid solution and stored at 4 C. Cells were dropped on frosted
microscope slides (Thermo Scientiﬁc), washed with 3:1 methanol:acetic acid
solution, heated for 5min at 70 C, and dried overnight. Slides were then rehy-
drated in coplin jars with PBS, ﬁxed with 4% formaldehyde (Sigma), washed
3 times with PBS and dehydrated in 70, 95, and 100% ethanol successively. Slides
were then air dried and hybridized with 20 ul of 200 nM TelC-Tamra peptide
nucleic acid (PNA) probe ((CCCTAA)3-Tamra, Panagene) in 70% formamide,
10mM Tris pH 7.5, 0.5% Odyessy blocking buffer (LiCor) according to the
manufactureras instructions. Slides were stained with DAPI and imaged using a
Nikon 80i upright microscope using a  100 oil objective.
Data availability. The atomic coordinates and structure factors for the POT1C-
TTP1 complex described here have been deposited in the Protein Data Bank under
the accession code 5UN7. The data that support the ﬁndings of this study are
available from the corresponding author on request.
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